114 related articles for article (PubMed ID: 18376798)
1. p53 and p21/WAF-1 overexpressions in prostatic adenocarcinoma.
Wan Muhaizan WM; Ahmad PK; Phang KS; Arni T
Malays J Pathol; 2006 Dec; 28(2):93-9. PubMed ID: 18376798
[TBL] [Abstract][Full Text] [Related]
2. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma.
Byrne RL; Horne CH; Robinson MC; Autzen P; Apakama I; Bishop RI; Neal DE; Hamdy FC
Br J Urol; 1997 Feb; 79(2):190-5. PubMed ID: 9052469
[TBL] [Abstract][Full Text] [Related]
3. Association of p53 immunoreactivity with high gleason tumor grade in prostatic adenocarcinoma.
Kallakury BV; Figge J; Ross JS; Fisher HA; Figge HL; Jennings TA
Hum Pathol; 1994 Jan; 25(1):92-7. PubMed ID: 7508886
[TBL] [Abstract][Full Text] [Related]
4. A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers.
Shiraishi T; Watanabe M; Muneyuki T; Nakayama T; Morita J; Ito H; Kotake T; Yatani R
Urol Int; 1998; 61(2):90-4. PubMed ID: 9873247
[TBL] [Abstract][Full Text] [Related]
5. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
[TBL] [Abstract][Full Text] [Related]
6. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
Sasor A; Wagrowska-Danilewicz M; Danilewicz M
Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
[TBL] [Abstract][Full Text] [Related]
7. hTERT expression in colorectal adenocarcinoma: correlations with p21, p53 expressions and clinicopathological features.
Lam AK; Ong K; Ho YH
Int J Colorectal Dis; 2008 Jun; 23(6):587-94. PubMed ID: 18322660
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical study of p21WAF1 and p53 proteins in prostatic cancer and their prognostic significance.
Matsushima H; Sasaki T; Goto T; Hosaka Y; Homma Y; Kitamura T; Kawabe K; Sakamoto A; Murakami T; Machinami R
Hum Pathol; 1998 Aug; 29(8):778-83. PubMed ID: 9712417
[TBL] [Abstract][Full Text] [Related]
9. Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents.
Girinsky T; Koumenis C; Graeber TG; Peehl DM; Giaccia AJ
Cancer Res; 1995 Sep; 55(17):3726-31. PubMed ID: 7543816
[TBL] [Abstract][Full Text] [Related]
10. Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer.
Romics I; Bánfi G; Székely E; Krenács T; Szende B
Pathol Oncol Res; 2008 Sep; 14(3):307-11. PubMed ID: 18415709
[TBL] [Abstract][Full Text] [Related]
11. Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer.
Karaburun Paker S; Kilicarslan B; Ciftcioglu AM; Oztekin S; Sargin FC; Erdogru T; Baykara M
Pathol Oncol Res; 2001; 7(3):209-12. PubMed ID: 11692148
[TBL] [Abstract][Full Text] [Related]
12. Expression of cell-cycle-regulated proteins pRb2/p130, p107, p27(kip1), p53, mdm-2, and Ki-67 (MIB-1) in prostatic gland adenocarcinoma.
Claudio PP; Zamparelli A; Garcia FU; Claudio L; Ammirati G; Farina A; Bovicelli A; Russo G; Giordano GG; McGinnis DE; Giordano A; Cardi G
Clin Cancer Res; 2002 Jun; 8(6):1808-15. PubMed ID: 12060621
[TBL] [Abstract][Full Text] [Related]
13. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
14. Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma.
Hayashi H; Miyamoto H; Ito T; Kameda Y; Nakamura N; Kubota Y; Kitamura H
Am J Pathol; 1997 Aug; 151(2):461-70. PubMed ID: 9250158
[TBL] [Abstract][Full Text] [Related]
15. Nuclear expression of p53, p21 and cyclin D1 is increased in bronchioloalveolar carcinoma.
McDonald JW; Pilgram TK
Histopathology; 1999 May; 34(5):439-46. PubMed ID: 10231419
[TBL] [Abstract][Full Text] [Related]
16. Biological aggressiveness evaluation in prostate carcinomas:immunohistochemical analysis of PCNA and p53 in a series of Gleason 6 (3+3) adenocarcinomas.
Cappello F; Palma A; Martorana A; Rappa F; Cabibi D; Barresi E; Melloni D; Farina F; Aragona F
Eur J Histochem; 2003; 47(2):129-32. PubMed ID: 12777208
[TBL] [Abstract][Full Text] [Related]
17. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.
Aljabery F; Shabo I; Gimm O; Jahnson S; Olsson H
Urol Oncol; 2018 Dec; 36(12):530.e7-530.e18. PubMed ID: 30539751
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
Tamboli P; Amin MB; Xu HJ; Linden MD
Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
[TBL] [Abstract][Full Text] [Related]
19. Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance.
Haitel A; Wiener HG; Neudert B; Marberger M; Susani M
Urology; 2001 Sep; 58(3):477-81. PubMed ID: 11549509
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
Valassiadou KE; Stefanaki K; Tzardi M; Datseris G; Georgoulias V; Melissas J; Tsiftsis DD; Delides G; Kanavaros P
Anticancer Res; 1997; 17(4A):2571-6. PubMed ID: 9252682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
